Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-01
2008-04-01
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S215000, C548S235000, C548S236000
Reexamination Certificate
active
11181640
ABSTRACT:
Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5232945 (1993-08-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 5994554 (1999-11-01), Kliewer et al.
patent: 6414001 (2002-07-01), Tomiyama et al.
patent: 6417212 (2002-07-01), Brooks et al.
patent: 6610696 (2003-08-01), Brooks et al.
patent: 6825222 (2004-11-01), Brooks et al.
patent: 6930120 (2005-08-01), Brooks et al.
patent: 6982278 (2006-01-01), Brooks et al.
patent: 7176224 (2007-02-01), Ardecky et al.
patent: 0 930 299 (1999-07-01), None
patent: 2 359 082 (2001-08-01), None
patent: WO 97 28115 (1997-08-01), None
patent: WO 97 31907 (1997-09-01), None
patent: WO 99 46232 (1999-09-01), None
patent: WO 01 16120 (2001-03-01), None
patent: WO 02 16331 (2002-02-01), None
patent: WO 02 16332 (2002-02-01), None
Bright et al (1997): STN International CAPLUS database (Columbus, Ohio), accession No. 1997:555602.
Sarges, R., et al.: “Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-Phenoxy-3-Phenylpropanoic Acids”; Journal of Medicinal Chemistry, vol. 39, No. 24, Nov. 22, 1996, pp. 4783-4803.
Cobb, J. E., et al. : “N-(2-Benzoylphenyl)-L-Tyrosine PPARGamma Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent”; Journal of Medicinal Chemistry, vol. 41, No. 25, Dec. 3, 1998, pp. 5055-5069.
Bright, S. W., et. al. : “Competitive Particle Concentration Fluorescence Immunoassays for Measuring Anti-Diabetic Drug Levels in Mouse Plasma”; Journal of Immunological Methods, vol. 207, No. 1, Aug. 22, 1997, pp. 23-31.
Brooks, D. , et al. : “Design and Synthesis of 2-methyl-2-{4-′2-′5-methyl-2-aryloxazol-4-yl)ethoxylphenoxy}propionic acids: A New Class of Dual PPARAlpha/Gamma Agonists”; Journal of Medicinal Chemistry, vol. 44, No. 13, Jun. 21, 2001, pp. 2061-2064.
Shinkai, H. et al. : “Isoxazolidine-3, 5-dione and Noncyclic 1,3-dicarbonyl Compounds as Hypoglycemic Agents”; Journal of Medicinal Chemistry, vol. 41, No. 11, May 21, 1998, pp. 1927-1933.
Murugesan, N., et al. : “Biphenylsulfonamide Endothelin Receptor Antogonists 2. Discovery of 4′-oxazoly-lbiphenylsulfonamides as a New Class of Poent, Highly Selective ET(A)Antagonists”; Journal of Medicinal Chemistry, vol. 43, No. 16, Aug. 10, 2000, pp. 3111-3117.
Malamas, M.S., et al. : “Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors fo 5-Lipoxygenase”; Journal of Medicinal Chemistry, vol. 39, No. 1, Jan. 5, 1996, pp. 237-245.
Merguro, K., et al. : “Studies on Antidiabetic Agents. VII. Synthesis and Hypoglycemic Activity fo 4-Oxazoleacetic Acid Derivatives”; Chemical & Pharmaceutical Bulletin, vol. 34, No. 7, 1986, pp. 2840-2851.
Bright, et al. ; STN International CAPLUS database (Columbus, Ohio) ; accession No. 1997:555602 (1997).
Yanping Xu, et al. , “Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/m Agonists,” J. Med. Chem, 47, pp. 2422-2425 (2004).
Brooks Dawn Alisa
Conner Scott Eugene
Dominianni Samuel James
Godfrey Alexander Glenn
Gossett Lynn Stacy
Eli Lilly and Company
Jang Soonhee
Vorndran-Jones MaCharri
LandOfFree
Oxazolyl-aryloxyacetic acid derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazolyl-aryloxyacetic acid derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazolyl-aryloxyacetic acid derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3915858